Design of clinical trials in advanced prostate cancer: Avoiding the dead ends

Frans M J Debruyne, Kenneth Watson, Daniel Petrylak, John Tod Isaacs, John Fitzpatrick, Paul Abrams

Research output: Contribution to journalArticle

Abstract

Despite more than 30 years of clinical trials, investigations in prostate cancer have not succeeded in making advances comparable to those in other branches of research, such as breast cancer. Indeed, prostate cancer trials have repeatedly run into a series of 'dead ends', as investigators face the problems of inadequate funding for research, treatments that result in only minimal improvements in survival, and lack of treatment options that have sufficient prospects for success. This article briefly reviews the strategies behind clinical investigations into prostate cancer over the last three decades, evaluates the pitfalls that have hindered research, and makes suggestions for the appropriate design of clinical trials that are safe and beneficial to patients while maintaining cost-effectiveness and accountability to patients and society.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalBJU International, Supplement
Volume96
Issue number2
DOIs
StatePublished - Dec 2005

Fingerprint

Prostatic Neoplasms
Clinical Trials
Research
Social Responsibility
Cost-Benefit Analysis
Research Personnel
Breast Neoplasms
Survival
Therapeutics

Keywords

  • Clinical trials
  • Prostate cancer
  • Prostate cancer treatment

ASJC Scopus subject areas

  • Urology

Cite this

Design of clinical trials in advanced prostate cancer : Avoiding the dead ends. / Debruyne, Frans M J; Watson, Kenneth; Petrylak, Daniel; Isaacs, John Tod; Fitzpatrick, John; Abrams, Paul.

In: BJU International, Supplement, Vol. 96, No. 2, 12.2005, p. 47-53.

Research output: Contribution to journalArticle

Debruyne, Frans M J ; Watson, Kenneth ; Petrylak, Daniel ; Isaacs, John Tod ; Fitzpatrick, John ; Abrams, Paul. / Design of clinical trials in advanced prostate cancer : Avoiding the dead ends. In: BJU International, Supplement. 2005 ; Vol. 96, No. 2. pp. 47-53.
@article{86ead0f7dbc94a329f50f8d5fa9afce2,
title = "Design of clinical trials in advanced prostate cancer: Avoiding the dead ends",
abstract = "Despite more than 30 years of clinical trials, investigations in prostate cancer have not succeeded in making advances comparable to those in other branches of research, such as breast cancer. Indeed, prostate cancer trials have repeatedly run into a series of 'dead ends', as investigators face the problems of inadequate funding for research, treatments that result in only minimal improvements in survival, and lack of treatment options that have sufficient prospects for success. This article briefly reviews the strategies behind clinical investigations into prostate cancer over the last three decades, evaluates the pitfalls that have hindered research, and makes suggestions for the appropriate design of clinical trials that are safe and beneficial to patients while maintaining cost-effectiveness and accountability to patients and society.",
keywords = "Clinical trials, Prostate cancer, Prostate cancer treatment",
author = "Debruyne, {Frans M J} and Kenneth Watson and Daniel Petrylak and Isaacs, {John Tod} and John Fitzpatrick and Paul Abrams",
year = "2005",
month = "12",
doi = "10.1111/j.1464-410X.2005.05947.x",
language = "English (US)",
volume = "96",
pages = "47--53",
journal = "BJU International, Supplement",
issn = "1465-5101",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Design of clinical trials in advanced prostate cancer

T2 - Avoiding the dead ends

AU - Debruyne, Frans M J

AU - Watson, Kenneth

AU - Petrylak, Daniel

AU - Isaacs, John Tod

AU - Fitzpatrick, John

AU - Abrams, Paul

PY - 2005/12

Y1 - 2005/12

N2 - Despite more than 30 years of clinical trials, investigations in prostate cancer have not succeeded in making advances comparable to those in other branches of research, such as breast cancer. Indeed, prostate cancer trials have repeatedly run into a series of 'dead ends', as investigators face the problems of inadequate funding for research, treatments that result in only minimal improvements in survival, and lack of treatment options that have sufficient prospects for success. This article briefly reviews the strategies behind clinical investigations into prostate cancer over the last three decades, evaluates the pitfalls that have hindered research, and makes suggestions for the appropriate design of clinical trials that are safe and beneficial to patients while maintaining cost-effectiveness and accountability to patients and society.

AB - Despite more than 30 years of clinical trials, investigations in prostate cancer have not succeeded in making advances comparable to those in other branches of research, such as breast cancer. Indeed, prostate cancer trials have repeatedly run into a series of 'dead ends', as investigators face the problems of inadequate funding for research, treatments that result in only minimal improvements in survival, and lack of treatment options that have sufficient prospects for success. This article briefly reviews the strategies behind clinical investigations into prostate cancer over the last three decades, evaluates the pitfalls that have hindered research, and makes suggestions for the appropriate design of clinical trials that are safe and beneficial to patients while maintaining cost-effectiveness and accountability to patients and society.

KW - Clinical trials

KW - Prostate cancer

KW - Prostate cancer treatment

UR - http://www.scopus.com/inward/record.url?scp=29944443428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944443428&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2005.05947.x

DO - 10.1111/j.1464-410X.2005.05947.x

M3 - Article

C2 - 16359439

AN - SCOPUS:29944443428

VL - 96

SP - 47

EP - 53

JO - BJU International, Supplement

JF - BJU International, Supplement

SN - 1465-5101

IS - 2

ER -